Visual abstract | FREEDOM2: Fedratinib vs BAT in in patients with MF previously treated with ruxolitinib

Myelofibrosis (MF) is a group of myeloproliferative neoplasms (MPN) that includes primary MF and secondary MF (post-polycythemia vera [PV] and post-essential thrombocythemia [ET] MF).¹ MF is characterized by abnormal clonal expansion of hematopoietic stem cells resulting in bone marrow fibrosis. Patients can be stratified into low, intermediate-1, intermediate-2, and high-risk categories, which correlate with patient prognoses.¹

Currently approved treatment options for patients with higher risk MF include hematopoietic stem cell transplantation and Janus kinase inhibitors, including ruxolitinib, fedratinib, momelotinib, and pacritinib.¹ Whilst ruxolitinib offers an effective frontline treatment for intermediate- and high-risk MF, ∼75% of patients discontinue treatment within 5 years due to disease progression or ruxolitinib intolerance, with poor survival rates following discontinuation. As such, treatments for patients with MF previously treated with ruxolitinib are a high unmet need.¹

Fedratinib was approved for the treatment of adults with intermediate-2 and high-risk primary MF, post-PV MF, and post-ET MF based on efficacy data from the phase III JAKARTA trial (NCT01437787).¹ Here, we present a visual abstract outlining the trial design and summarizing key efficacy and safety data from the phase III FREEDOM2 trial (NCT03952039) investigating fedratinib vs best available therapy in patients with MF previously treated with ruxolitinib (N = 201) published in Lancet Haematology by Claire Harrison et al.¹

 

^{This educational resource is independently supported by Bristol Myers Squibb. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.}